417 related articles for article (PubMed ID: 35738255)
1. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids.
Gupta B; Rai R; Oertel M; Raeman R
Semin Liver Dis; 2022 May; 42(2):122-137. PubMed ID: 35738255
[TBL] [Abstract][Full Text] [Related]
2. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
3. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Chu H; Duan Y; Yang L; Schnabl B
Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
[TBL] [Abstract][Full Text] [Related]
4. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment.
Yang M; Zhang CY
World J Gastroenterol; 2021 Feb; 27(8):677-691. PubMed ID: 33716447
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
6. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
7. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
11. [The role of intestinal microbiota in the development of non-alcoholic fatty liver disease].
Tumani MF; Tapia G; Aguirre C; Obregón AM; Pettinelli P
Rev Med Chil; 2021 Apr; 149(4):570-579. PubMed ID: 34479345
[TBL] [Abstract][Full Text] [Related]
12. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
Shao L; Song Y; Shi JP
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.
Park E; Jeong JJ; Won SM; Sharma SP; Gebru YA; Ganesan R; Gupta H; Suk KT; Kim DJ
Cells; 2021 Oct; 10(10):. PubMed ID: 34685614
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
[TBL] [Abstract][Full Text] [Related]
16. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
17. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.
Aqel B; DiBaise JK
Nutr Clin Pract; 2015 Dec; 30(6):780-6. PubMed ID: 26449892
[TBL] [Abstract][Full Text] [Related]
18. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
19. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
Ni Y; Ni L; Zhuge F; Fu Z
Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]